Sling Brings Potential Oral Competition To Amgen’s Tepezza In TED
With positive Phase IIb/III data for IGF-1r inhibitor linsitinib, privately held Sling plans to move into Phase III and compete in thyroid eye disease on convenience and safety.
With positive Phase IIb/III data for IGF-1r inhibitor linsitinib, privately held Sling plans to move into Phase III and compete in thyroid eye disease on convenience and safety.